Overview Request Sample Pages Request Customization Download PDF
You are viewing: Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market analysis

The Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market was valued at $1.5 Million in 2024 and projected to reach to $1.7 Million by 2029, representing a compound annual growth rate of CAGR 2.5%. Other GCC Countries' AMD drugs market is positioned for gradual expansion as healthcare systems strengthen and geriatric populations increase.

Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market Trends and Insights

  • Other GCC Countries represents a modest but growing segment within the broader GCC pharmaceutical landscape, driven by an aging population and increasing prevalence of age-related eye disorders.
  • The market in Other GCC Countries reflects moderate demand for AMD therapeutics, with limited but steady adoption of anti-VEGF agents and other treatment modalities. Other GCC Countries faces unique market dynamics characterized by developing healthcare infrastructure and rising awareness of vision-threatening diseases among elderly populations.
  • Between 2024 and 2029, Other GCC Countries is expected to experience gradual market expansion as healthcare spending increases and access to specialized ophthalmologic treatments improves.
  • The relatively conservative growth rate in Other GCC Countries compared to global benchmarks underscores the region's smaller patient population and emerging market maturity for AMD therapeutics..

Key Market Statistics

  • CAGR (2024-2029) CAGR 2.5%
  • Market Size, 2024 ~USD 1.5 Million
  • Forecast, 2029 ~USD 1.7 Million
  • Country Other GCC Countries

Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market Overview

Modest Market Size with Growth Potential :

Other GCC Countries' AMD drugs market was valued at USD 1.5 million in 2024, representing a smaller but emerging segment within the GCC region. Despite its current size, the market demonstrates steady expansion potential driven by demographic shifts and healthcare infrastructure improvements.

Conservative CAGR of 2.5% Through 2029 :

The market is projected to grow at a CAGR of 2.5% from 2024 to 2029, reaching USD 1.7 million by forecast end. This slower growth rate compared to the global CAGR of 10.7% reflects the region's smaller patient population and developing healthcare adoption rates for specialized ophthalmology treatments.

Aging Population Driving Disease Prevalence :

Other GCC Countries are experiencing demographic aging, which is increasing the incidence of age-related macular degeneration. This population trend is a primary growth driver, as AMD predominantly affects individuals over 50 years old, creating sustained demand for therapeutic interventions.

Lagging Behind Global Market Dynamics :

With a global AMD drugs market CAGR of 10.7%, Other GCC Countries significantly underperforms the broader market. This gap suggests opportunities for market penetration, improved healthcare access, and increased awareness campaigns to align regional growth with international standards.

Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market Dynamics

  • The region's modest current valuation of USD 1.5 million reflects limited market penetration and lower treatment adoption rates compared to developed markets.
  • However, improving healthcare infrastructure, rising disposable incomes, and greater awareness of vision-threatening diseases are expected to support incremental growth through 2029. The projected growth to USD 1.7 million by 2029 indicates emerging opportunities for pharmaceutical manufacturers and healthcare providers.
  • While the 2.5% CAGR remains conservative relative to global benchmarks, it reflects realistic market conditions in smaller GCC economies.
  • Strategic partnerships with local healthcare providers, patient education initiatives, and regulatory streamlining could accelerate market development and narrow the performance gap with faster-growing regions..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Other GCC Countries AMD drugs market valued at USD 1.5 million in 2024, with projected growth to USD 1.7 million by 2029.
    • Other GCC Countries exhibits a 2.5% CAGR, reflecting modest but steady market expansion driven by aging demographics.
    • Other GCC Countries market growth is constrained by limited patient population and developing healthcare infrastructure compared to larger GCC economies.
    • Other GCC Countries represents an emerging opportunity for AMD therapeutics as healthcare awareness and spending increase through 2029.

    Age-related Macular Degeneration (AMD) Drugs Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment BIOSIMILARS (Approval Type)
    Forecast Period 2024-2029
    Growth Rate CAGR of 10.7% from 2024 to 2029
    Largest Segment BIOLOGICS (Approval Type)
    Market Size Base Year (Billions) ~USD 10.45 (2024)
    Revenue Forecast (Billions) ~USD 17.37 (2029)
    Segments Covered Product, Molecule, Approval Type, Type Of Amd, End User

    Other GCC Countries Age-related Macular Degeneration (AMD) Drugs Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Eylea & Eylea Hd
    • Lucentis
    • Other Products
    • Syfovre
    • Vabysmo

    By Molecule

    • Aflibercept
    • Faricimab
    • Other Molecules
    • Pegcetacoplan
    • Ranibizumab

    By Approval Type

    • Biologics
    • Biosimilar
    • Biosimilars

    By Type Of Amd

    • Dry Amd
    • Wet Amd

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Specialty Centers

    Target Audience

    • Pharmaceutical Manufacturers : Companies developing or marketing AMD therapeutics need region-specific data to assess market viability, set realistic sales targets, and develop localized go-to-market strategies for Other GCC Countries' unique healthcare environment.
    • Healthcare Investment Firms : Private equity and venture capital investors evaluating opportunities in GCC healthcare require granular market analysis to identify growth potential, assess risk-return profiles, and make capital allocation decisions in smaller Gulf pharmaceutical markets.
    • Medical Device and Diagnostic Companies : Organizations providing AMD diagnostic tools and monitoring devices need market sizing data to understand patient populations, healthcare spending patterns, and distribution opportunities specific to Other GCC Countries.
    • Healthcare Policy and Government Bodies : Regional health ministries and regulatory agencies use market intelligence to inform healthcare policy, budget allocation, and pharmaceutical reimbursement strategies tailored to Other GCC Countries' disease burden and economic capacity.
    • Market Research and Consulting Firms : Research organizations and business consultants require detailed regional market cutouts to support client advisory services, competitive intelligence, and strategic planning engagements focused on GCC pharmaceutical and healthcare sectors.

    Reasons to Buy this Report

    • Targeted Regional Market Intelligence : Gain exclusive insights into Other GCC Countries' AMD drug market dynamics, distinct from broader GCC or Middle Eastern analyses. This focused cutout provides precise data on market size, growth trajectories, and regional-specific factors affecting pharmaceutical demand in smaller Gulf economies.
    • Strategic Market Entry Planning : Identify growth opportunities and market gaps in an underperforming region relative to global standards. With a 2.5% CAGR versus 10.7% globally, this analysis reveals untapped potential for companies seeking to establish or expand presence in emerging GCC pharmaceutical markets.
    • Competitive Positioning Insights : Understand the competitive landscape specific to Other GCC Countries, including market saturation levels, pricing dynamics, and distribution challenges. This regional focus enables better competitive benchmarking and differentiation strategies tailored to local market conditions.
    • Demographic and Healthcare Trend Analysis : Access detailed information on aging population trends, disease prevalence patterns, and healthcare infrastructure development in Other GCC Countries. These insights are critical for forecasting demand and aligning product development with regional healthcare needs.
    • Investment and Partnership Decision Support : Make informed decisions on market investments, licensing agreements, and strategic partnerships in Other GCC Countries. Precise market forecasts through 2029 provide confidence for long-term business planning and resource allocation in this emerging pharmaceutical segment.

    Frequently asked questions

    What is the current market size of AMD drugs in Other GCC Countries?

    Other GCC Countries AMD drugs market was valued at USD 1.5 million in 2024 and is expected to grow to USD 1.7 million by 2029.

    What is the projected CAGR for AMD drugs in Other GCC Countries?

    Other GCC Countries is projected to grow at a CAGR of 2.5% from 2024 to 2029, reflecting gradual market expansion.

    What factors drive AMD drug market growth in Other GCC Countries?

    Other GCC Countries market growth is driven by an aging population, increasing healthcare spending, and rising awareness of age-related eye diseases.

    How does Other GCC Countries compare to the global AMD drugs market?

    Other GCC Countries grows at 2.5% CAGR compared to the global market CAGR of 10.7%, indicating a more mature and slower-growing regional segment.

    What challenges does the AMD drugs market face in Other GCC Countries?

    Other GCC Countries faces challenges including limited patient population, developing healthcare infrastructure, and lower treatment adoption rates compared to developed markets.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global age-related macular degeneration (AMD) drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources. Corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; white papers; press releases; and trade, business, and professional associations, were also used as secondary sources for this research report. Secondary data was collected and analyzed to arrive at the overall size of the global Age-Related Macular Degeneration (AMD) drugs market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global Age-Related Macular Degeneration (AMD) drugs market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as ophthalmologists, and personnel from specialty centers and long-term care facilities, along with experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Age-Related Macular Degeneration (AMD) Drugs Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the age-related macular degeneration (AMD) drugs market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and market have been identified through extensive primary and secondary research.
    • The revenues generated from the age-related macular degeneration (AMD) drugs business of leading players have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Age-Related Macular Degeneration (AMD) Drugs Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Age-Related Macular Degeneration (AMD) Drugs Market Size, and Share

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

    Market Definition

    Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects individuals over the age of 50, leading to the deterioration of central vision due to damage to the macula, the part of the retina responsible for sharp, detailed vision. AMD is classified into two main types: dry (non-neovascular) and wet (neovascular). Dry AMD involves the gradual breakdown of light-sensitive cells in the macula, often indicated by the presence of drusen (yellow deposits). Wet AMD is characterized by the growth of abnormal blood vessels beneath the retina, which leak fluid or blood, causing rapid vision loss. This market includes the market for marketed biologics and biosimilars along with Phase 3 molecules for the treatment of AMD.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty centers
    • Long-term care facilities
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the global age-related macular degeneration (AMD) drugs market based on product, molecule, type of AMD, approval type, end user, and region
    • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa
    • To profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
    • To track and analyze competitive developments such as acquisitions, product/ service launches, expansions, agreements, partnerships, and collaborations in the market

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe Age-related macular degeneration (AMD) drugs market, by country
    • Further breakdown of the Rest of Asia Pacific Age-related macular degeneration (AMD) drugs market, by country
    • Further breakdown of the Rest of Latin America and Middle East & Africa Age-related macular degeneration (AMD) drugs market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Get the Full Age-related Macular Degeneration (AMD) Drugs Market Report

    Full forecast, segment splits, and company analysis for all Age-related Macular Degeneration (AMD) Drugs Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status